Serum GFAP and EGFR as Supportive Diagnostic Biomarker of Glioma Patients: A Single-Center Study

Dody Priambada; Muhamad Thohar Arifin; Surya Pratama Briliantika; Dian Widyaningrum; Abdi Saputro; Azka Tajussyarof El Muzakka; Yuriz Bakhtiar; Krisna Tsaniadi Prihastomo; Zainal Muttaqin

doi:10.3889/oamjms.2022.9021

Authors

Dody Priambada Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia https://orcid.org/0000-0003-4908-3903
Muhamad Thohar Arifin Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia https://orcid.org/0000-0003-2363-8026
Surya Pratama Briliantika Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia
Dian Widyaningrum Department of Clinical Pathology, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia
Abdi Saputro Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia
Azka Tajussyarof El Muzakka Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia
Yuriz Bakhtiar Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia
Krisna Tsaniadi Prihastomo Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia https://orcid.org/0000-0002-0792-2943
Zainal Muttaqin Department of Neurosurgery, Faculty of Medicine, Universitas Diponegoro, Dr. Kariadi Hospital, Semarang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.9021

Keywords:

Glioma, High-grade glioma, Serum GFAP, Serum EGFR

Abstract

Background : High grade Gliomas (HGGs) (World Health Organization grade III and IV) are aggressive brain tumors with a poor prognosis. Serum concentrations of GFAP and EGFR are theoretically raised in glioma patients, especially primary HGGs

Aim : To look at serum levels of GFAP and EGFR in patients with Gliomas (Low Grade and High-Grade Glioma) and see if they were related to clinical outcome, MRI parameter and pathological features.

Method : Between 2020-2021, pre-operative blood samples were taken from 39 patients with radiologically diagnosed glioma who were performed for tumour excision. The time between blood collection and surgical resection was an average of 10 days. GFAP and EGFR serum were compared in glioma and non-glioma patients.

Result : Glioma patients had average of serum GFAP 747.93 + 1349.49 pg/ml and average of Serum EGFR 9.25 + 3.17 ng/ml. Non glioma average of GFAP and EGFR respectively were 292.91 + 369.30 pg/ml and 7.81 + 3.38 ng/ml.From all variable, we performed normality test using the Saphiro-wilk normality test and all variable were no normally distribution with p<0.05

Conclusion : Circulating GFAP and EGFR are promising method for “supportive” methods for differentiate between glioma and non-glioma patients, especially high grade glioma

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Salem A, Hashem SA, Al-Rashdan A, Ezam N, Nour A, Alsharbaji A, et al. The challenges of managing glioblastoma multiforme in developing countries: A trade-off between cost and quality of care. Hematol Oncol Stem Cell Ther. 2011;4(3):116-20. https://doi.org/10.5144/1658-3876.2011.116 PMid:21982884 DOI: https://doi.org/10.5144/1658-3876.2011.116

Wei P, Zhang W, Yang LS, Zhang HS, Xu XE, Jiang YH, et al. Serum GFAP autoantibody as an ELISA-detectable glioma marker. Tumor Biol. 2013;34(4):2283-92. https://doi.org/10.1007/s13277-013-0770-7 PMid:23589055 DOI: https://doi.org/10.1007/s13277-013-0770-7

Kiviniemi A, Gardberg M, Frantzén J, Parkkola R, Vuorinen V, Pesola M, et al. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: Correlation to tumor volume, molecular markers, and progression-free survival. J Neurooncol. 2015;124(2):237-45. https://doi.org/10.1007/s11060-015-1829-7 PMid:26033547 DOI: https://doi.org/10.1007/s11060-015-1829-7

Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013;15(1):91-6. https://doi.org/10.1093/neuonc/nos268 PMid:23095230 DOI: https://doi.org/10.1093/neuonc/nos268

Tichy J, Spechtmeyer S, Mittelbronn M, Hattingen E, Rieger J, Senft C, et al. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neurooncol. 2015;126(2):361-9. https://doi.org/10.1007/s11060-015-1978-8 PMid:26518540 DOI: https://doi.org/10.1007/s11060-015-1978-8

Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, Seifert V, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007;130(12):3336-41. https://doi.org/10.1093/brain/awm263 PMid:17998256 DOI: https://doi.org/10.1093/brain/awm263

Yang Z, Wang KK. Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364-74. https://doi.org/10.1016/j.tins.2015.04.003 PMid:25975510 DOI: https://doi.org/10.1016/j.tins.2015.04.003

Uceda-Castro R, van Asperen JV, Vennin C, Sluijs JA, van Bodegraven EJ, Margarido AS, et al. GFAP splice variants fine-tune glioma cell invasion and tumour dynamics by modulating migration persistence. Sci Rep. 2022;12(1):1-14. https://doi.org/10.1038/s41598-021-04127-5 PMid:35013418 DOI: https://doi.org/10.1038/s41598-021-04127-5

Lim DA, Cha S, Mayo MC, Chen MH, Keles E, Vandenberg S, et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 2007;9(4):424-9. https://doi.org/10.1215/15228517-2007-023 PMid:17622647 DOI: https://doi.org/10.1215/15228517-2007-023